# Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery

> **NCT07550374** · PHASE1 · NOT_YET_RECRUITING · sponsor: **iRegene Therapeutics Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **BIOLOGICAL:** NouvNeu001 injection

## Key facts

- **NCT ID:** NCT07550374
- **Lead sponsor:** iRegene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-04
- **Final completion:** 2031-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550374, "Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07550374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*